Skip to main content

Building Immune-Radiotherapy Collaborations

Cardiff Mercure Hotel

 

This meeting focused on the immune aspect of radiotherapy is run with the support of industry and in collaboration with the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group, Cancer Research UK's RadNet and the British Society for Immunology (BSI).

It offers a great opportunity to enhance cross-community interdisciplinary engagement with a broad collection of speakers who are national and international leaders as well as research leaders for the future.

This is in line with the objectives of the NCRI and BSI Strategic Partnership that aims to bring communities together to drive collaborations that address current challenges in immunotherapy. The sessions will cover what is known and what we are learning pre-clinically and translationally as well as how we can develop clinical trials of the future to improve patient care.


Programme

8:50 Introduction and Welcome: Prof Richard Adams,  Cardiff University

Session 1: Pre-clinical Optimisation
Chair: Prof Awen Gallimore, Cardiff University

9:00 – 9:30    Prof. Sandra Demaria,  Weill Cornell Medical College, New York USA.
Improving responses to radiotherapy using immunotherapy
9:35 – 10:00    Prof. Eileen Parkes, Oxford University
Immune effects of radiation in DNA repair deficient/ chromosomally unstable cancers
10:05 – 10:30    Prof. Tim Illidge, University of Manchester and Christie Hospital
Pre-clinical models for Immune-radiotherapy
10:35 – 10:45    Abstract presentation

 

Session 2: Translating Evidence
Chair: Prof Alan Melcher; Institute of Cancer Research

11:15 – 11:40    Dr. Anna Wilkins, Institute of Cancer Research
Practical challenges of collecting patient samples for immune readouts
11:45 – 12:10    Mr Campbell Roxburgh, The Beatson Institute, University of Glasgow
Priming the immune system in rectal cancer
12:15 – 12:40    Dr. Pablo Nenclares, Institute of Cancer Research, London
Tracking immune responses to HPV, with TCRseq
12:45 – 1:00    Abstract presentation

 

Session 3: Learning from clinical trials
Chair: Dr Anthony Kong

1:45 – 2:20    Prof. Silvia Formenti, Weill Cornell Medical College, New York, USA.
Brain mets/abscopal effect
2:25 – 2.45    Dr. Eleanor Cheadle, University of Manchester
Learning from the PORT trial
2.45 – 3.10   Speaker TBC
Learning from Rectal cancer studies
3.10 – 3.30    Dr. Nick West, University of Leeds
RadPath

 

Session 4: Designing to deliver
Chair Prof. Richard Adams

4.00 – 4.45    Dr. Sarah Brown, LICTR, University of Leeds
Optimising design in early phase trials
4.25 – 4.40    Tim Ward:
The Patients voice in immunotherapy radiotherapy trials

Prof Richard Adams: Overview and Close


Register

You can register to attend this event here.